Literature DB >> 9000042

Immune complexes bound to the primate erythrocyte complement receptor (CR1) via anti-CR1 mAbs are cleared simultaneously with loss of CR1 in a concerted reaction in a rhesus monkey model.

R P Taylor1, P J Ferguson, E N Martin, J Cooke, K L Greene, K Grinspun, M Guttman, S Kuhn.   

Abstract

In the circulation of primates, C3b-opsonized immune complexes (IC) bound to erythrocyte (E) CR1 are taken to the liver and spleen where IC are removed and destroyed without lysis or sequestration of E. Individuals with diseases associated with IC processing often have decreased E CR1 levels, and in previous primate animal models of IC disease, E CR1 was shown to be reduced, but the relationship between IC processing and CR1 loss remained to be clarified. We have developed a simple model to study this question. In naive (nonimmunized) rhesus monkeys, E-bound mouse anti-CR1 mAbs (1500 IgG/E) are not rapidly cleared from the circulation. Infusion of monkey anti-mouse IgG leads to rapid indirect binding of this second antibody to E CR1. Subsequently, in what appears to be a concerted reaction, CR1-bound nascent IC are rapidly cleared from the circulation and CR1 is removed from E at the same rate. Clearance of bound IC and loss of CR1 were both independently followed by RIA. Imaging studies localized the cleared anti-CR1 mAbs to the liver. Western blots indicated that the loss of CR1 was not due to a conformational change, and E CR1 levels returned to normal in 2-3 weeks, suggesting that the return was associated with synthesis of new E. Our findings suggest that the key step in the clearance mechanism requires recognition (possibly by Fc receptors) of IC-like material associated with E CR1, and this leads to loss of CR1 and uptake of the CR1-IC substrate by liver phagocytic cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9000042     DOI: 10.1006/clin.1996.4286

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  11 in total

1.  Effect of plasmapheresis on ligand binding capacity and expression of erythrocyte complement receptor type 1 (CR1) of patients with systemic lupus erythematosus (SLE).

Authors:  I Csípö; E Kiss; P Soltész; P Antal-Szalmás; G Szegedi; J H Cohen; R P Taylor; M Kávai
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 2.  Drug delivery by red blood cells: vascular carriers designed by mother nature.

Authors:  Vladimir R Muzykantov
Journal:  Expert Opin Drug Deliv       Date:  2010-04       Impact factor: 6.648

3.  A transgenic mouse model for studying the clearance of blood-borne pathogens via human complement receptor 1 (CR1).

Authors:  A Repik; S E Pincus; I Ghiran; A Nicholson-Weller; D R Asher; A M Cerny; L S Casey; S M Jones; S N Jones; N Mohamed; L B Klickstein; G Spitalny; R W Finberg
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

4.  Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection.

Authors:  Nuntaya Punyadee; Dumrong Mairiang; Somchai Thiemmeca; Chulaluk Komoltri; Wirichada Pan-Ngum; Nusara Chomanee; Komgrid Charngkaew; Nattaya Tangthawornchaikul; Wannee Limpitikul; Sirijitt Vasanawathana; Prida Malasit; Panisadee Avirutnan
Journal:  J Virol       Date:  2014-11-19       Impact factor: 5.103

5.  Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques.

Authors:  L Zhang; P J Dailey; T He; A Gettie; S Bonhoeffer; A S Perelson; D D Ho
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

Review 6.  Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.

Authors:  Carlos H Villa; Daniel C Pan; Sergei Zaitsev; Douglas B Cines; Donald L Siegel; Vladimir R Muzykantov
Journal:  Ther Deliv       Date:  2015-07

7.  Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.

Authors:  Rashmi Sharma; Huiwu Zhao; Fetweh H Al-Saleem; Ahmed Syed Ubaid; Rama Devudu Puligedda; Andrew T Segan; Margaret A Lindorfer; Rodney Bermudez; Md Elias; Sharad P Adekar; Lance L Simpson; Ronald P Taylor; Scott K Dessain
Journal:  Mol Immunol       Date:  2013-11-01       Impact factor: 4.407

Review 8.  The role of complement in tumor growth.

Authors:  Ruben Pio; Leticia Corrales; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

Review 9.  Innate Immunity in the Persistent Inflammation, Immunosuppression, and Catabolism Syndrome and Its Implications for Therapy.

Authors:  Hiroyuki Horiguchi; Tyler J Loftus; Russell B Hawkins; Steven L Raymond; Julie A Stortz; McKenzie K Hollen; Brett P Weiss; Elizabeth S Miller; Azra Bihorac; Shawn D Larson; Alicia M Mohr; Scott C Brakenridge; Hironori Tsujimoto; Hideki Ueno; Frederick A Moore; Lyle L Moldawer; Philip A Efron
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

Review 10.  Complement and systemic lupus erythematosus.

Authors:  Mark J Walport
Journal:  Arthritis Res       Date:  2002-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.